Comparative antibacterial activity of a new oral cephalosporin, BMY-28100 | Zendy

N X Chin | Zendy; H. C. Neu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative antibacterial activity of a new oral cephalosporin, BMY-28100

Author(s) -

N X Chin,

H. C. Neu

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.3.480

Subject(s) - microbiology and biotechnology , bacteroides fragilis , cephalosporin , cefaclor , providencia , citrobacter freundii , enterobacter , citrobacter , haemophilus influenzae , neisseria gonorrhoeae , enterococcus faecalis , klebsiella pneumoniae , listeria , biology , haemophilus parainfluenzae , escherichia coli , listeria monocytogenes , antibiotics , bacteria , biochemistry , genetics , gene

BMY-28100 is a new oral cephalosporin which had in vitro activity superior to that of cephalexin and cefaclor against staphylococci, beta-hemolytic streptococcal species, and Streptococcus pneumoniae. It inhibited beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, 50% of Streptococcus faecalis isolates, Listeria monocytogenes, and 50 to 75% of Escherichia coli and Klebsiella species at less than or equal to 8 micrograms/ml, but high producers of beta-lactamase were resistant. Enterobacter, Citrobacter, Morganella, Providencia, and Pseudomonas species and Bacteroides fragilis were resistant. BMY-28100 was more stable than cefaclor against hydrolysis by beta-lactamases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research